What factors drove the changes in Community Health's revenue and profit?

What were the key takeaways from Community Health’s earnings call?

What is Community Health's latest dividend and current dividend yield?

What does Community Health do and what are its main business segments?

Did Community Health beat or miss consensus estimates last quarter?

What guidance did Community Health's management provide for the next earnings period?

What were the key takeaways from Community Health's earnings call?

What is the market's earnings forecast for Community Health next quarter?

- **Revenue Resilience**: 2.1% same-store net revenue growth despite ACA headwinds, driven by rate and acuity improvements.
- **AI-Driven Efficiency**: $50 million in ERP savings and AI tools reducing falls and improving documentation accuracy.
- **Debt Reduction Progress**: Leverage down to 6.6x in 2025, with Huntsville sale expected to lower net debt to $9.2 billion.
- **2026 Outlook**: Core EBITDA growth of 4%, offset by $80-90 million from divestitures and $20-30 million ACA impact, targeting $1.34-1.49 billion EBITDA.

**【CEO Summary Section】**
- **Revenue Growth and Strategic Investments**: CEO Kevin Hammons highlighted a 2.1% year-over-year increase in same-store net revenue, driven by rate growth and acuity improvements. Investments in AI and clinical programs (e.g., heart surgeries up 16% in 2025) are enhancing patient care and operational efficiency.
- **Divestitures and Balance Sheet Strengthening**: The company completed $623 million in divestitures, reducing leverage to 6.6x at year-end 2025. Proceeds from Huntsville divestiture (expected Q2 2026) will further reduce net debt to $9.2 billion.
- **Vision and Priorities**: Focus on improving quality, patient experience, and employee satisfaction, with 2026 goals including 4% core EBITDA growth and $350-400 million in capital spending.

**【CFO Financial Commentary】**
- **2025 Financial Results**: Adjusted EBITDA of $395 million (12.7% margin) and $543 million in cash flows from operations. Medical specialist fees grew 4.6% YoY, with plans to mitigate 5-8% annual growth through in-sourcing.
- **2026 Guidance**: Net revenue $11.6-12.0 billion, EBITDA $1.34-1.49 billion, reflecting $80-90 million EBITDA impact from 2026 divestitures and $20-30 million headwind from ACA exchange enrollment declines.
- **Debt Reduction**: Partial redemption of $223 million in senior notes at 103%, reducing net debt to $9.2 billion post-Huntsville sale.

**【Q&A Key Highlights】**
- **Divestiture Outlook**: CEO indicates limited remaining divestiture opportunities, with focus on core portfolio optimization.
- **AI and Technology**: $50 million in ERP-related savings in 2025, with AI tools improving safety (e.g., virtual patient sitters) and revenue cycle efficiency.
- **ACA Impact**: CFO estimates $20-30 million EBITDA impact from 20% exchange enrollment decline, offset by low co-pay collection rates.
- **Cash Flow Management**: 2026 extra pay period (27 vs. 26) creates $140 million headwind, balanced by AR collections and AP management improvements.

Community Health Systems, Inc. (CYH) Q4 2025 Earnings Call Transcript

- **Revenue Expansion**: 6% YoY same-store net revenue growth, driven by rate increases and state programs.
- **Margin Improvement**: Adjusted EBITDA margin 12.2%, up 100bps YoY, despite higher acuity.
- **Debt Reduction**: Leverage down to 6.7x, with refinanced debt maturing in 2029.
- **Strategic Growth**: Investing in new service lines and recruiting 160+ physicians/Apps.
- **Challenges**: Outpatient volume softness persists, medical specialist fees rising.

**【Management Remarks】**
- **Revenue Growth and Strategic Investments**: Same-store net revenue increased 6% YoY, driven by rate growth and state-directed payments. Inpatient admissions were flat, while outpatient surgeries remained soft. The company invested in new service lines (e.g., robotic surgery, neurosurgery) and recruited 160+ new physicians/Apps.
- **Financial Health**: Leverage reduced to 6.7x (from 7.4x in 2024), with $1.743 billion of Senior Secured Notes refinanced to 2034. A $28 million legal settlement boosted Q3 results.
- **Operational Efficiency**: Marginal margin expansion despite higher acuity mix, with disciplined cost control in labor and supplies.

**【CFO Financial Commentary】**
- **Profitability**: Adjusted EBITDA of $376 million (+8.3% YoY), margin 12.2% (up 100bps). Excluding the legal gain, margin was 11.4% (+20bps).
- **Volume Metrics**: Same-store inpatient admissions +1.3% YoY, adjusted admissions +0.3%. Outpatient surgeries and ED visits declined 2.2% and 1.3%, respectively.
- **Cost Management**: Labor and supplies expenses were stable/declining, with medical specialist fees up 4% YoY but expected to rise in 2026.
- **Liquidity**: Year-to-date cash flows from operations $277 million, with adjusted free cash flow slightly negative. Refinancing extended maturities to 2029, supporting $195 million lab divestiture proceeds.

**【Q&A Highlights】**
- **Volume Trends**: Sequential improvement in payer mix and volumes, but outpatient surgeries remain constrained by consumer demand. Q4 expected to reflect seasonal recovery.
- **Capital Deployment**: Positive free cash flow for 2025 may fund growth (e.g., ASCs, freestanding EDs) or deleverage.
- **2026 Outlook**: Medicare rate increases and rural health funding could offset outpatient pressures. AI tools aim to mitigate medical specialist fee growth.
- **Risks**: Economic headwinds, immigration policy impacts, and flu season uncertainty.

Community Health Systems, Inc. (CYH) Q3 2025 Earnings Call Transcript

- **CEO Transition**: Tim Hingtgen retiring in September; Kevin Hammons to become CEO.
- **Revenue Growth**: Same-store net revenue +6.5% YoY, driven by Medicaid SDPPs.
- **EBITDA Guidance**: Tightened to $1.45B-$1.55B due to volume headwinds.
- **OBBBA Impact**: $300M-$350M cumulative EBITDA reduction over 13 years, starting 2027.
- **Cash Flow Outlook**: Positive free cash flow expected in second half of 2025.
- **Strategic Initiatives**: ASC expansion, 200+ new provider hires, and SDPP program growth.

**【CEO Summary Section】**
- CEO Tim Hingtgen announced his retirement effective September 2025, with Kevin Hammons succeeding as CEO. Hingtgen highlighted CHS's Q2 2025 performance: same-store net revenue grew 6.5% YoY, driven by rate increases and Medicaid state-directed payment programs (SDPPs) in New Mexico and Tennessee. Despite lower-than-expected patient volumes (adjusted admissions down 0.7%), CHS emphasized strategic investments in ambulatory surgery centers (ASCs), provider recruitment (200+ new hires), and service line expansions in key markets like Knoxville and Birmingham. The company remains confident in its ability to capture demand as consumer confidence recovers.

**【CFO Financial Commentary】**
- Q2 2025 adjusted EBITDA was $380 million (down 2% YoY), with margins at 12.1% (flat YoY). Key financial highlights:
  - **Revenue Growth**: Same-store net revenue up 6.5% YoY, including $75 million from SDPPs.
  - **Expense Management**: Labor costs +4% YoY (aligned with expectations), contract labor down $5 million YoY. Supplies expense stable as a percentage of revenue.
  - **Cash Flow**: Q2 cash flow from operations was $87 million ($282 million YTD, excluding $74 million in tax payments). Free cash flow expected to turn positive in the second half.
  - **Guidance Update**: Full-year EBITDA revised to $1.45B-$1.55B (prior: $1.52B-$1.62B), reflecting lower volume growth and SDPP timing.
  - **OBBBA Impact**: Projected $300M-$350M cumulative EBITDA reduction over 13 years (2027-2038), with no 2025 impact. CHS will pursue legislative fixes.

**【Q&A Key Highlights】**
- **Volume Trends**: Q2 volumes were depressed by consumer confidence, but June saw stabilization. Full-year adjusted admissions now expected at 0%-1% vs. prior 2%-3% guidance.
- **SDPP Updates**: Florida and Indiana SDPPs likely approved, with Florida offering modest tailwinds and Indiana a material benefit. Alabama and Arkansas SDPPs remain uncertain.
- **Leverage Target**: Aiming for below 5.5x by 2027, with $300 million in expected 2025 proceeds from Labcorp sale and Tennova contingent consideration. Refinancing of 2027 debt is a priority.
- **Medicare Performance**: Medicare volumes remain stable, with minimal impact from economic factors.
- **OBBBA Tax Benefits**: Restored interest deductions will reduce annual cash taxes by $40M-$60M starting 2026.


Community Health Systems, Inc. (CYH) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Same-store admissions +4% YoY, driven by flu season and strategic investments. 
- **Divestiture Progress**: $1B+ proceeds used to reduce debt; potential exceedance of target. 
- **Cost Management**: Anesthesia fees up 9% YoY, offset by in-sourcing initiatives. 
- **Leverage Improvement**: Net debt/EBITDA down to 7.1x from 7.4x YoE. 
- **Innovation Momentum**: Robotics caseloads up significantly; ASC expansion continues. 
- **Risk Watch**: Payer downgrades headwind expected until Q4 2025; DPP approvals critical for $100-125M EBITDA boost.

**【CEO Summary Section】**
- First-quarter 2025 results show strong momentum with same-store admissions up 4% YoY, driven by a heavier flu season and strategic investments in acute and ambulatory care. 
- Gross proceeds from divestitures total $1 billion+ to date, with additional transactions in advanced discussions. 
- Emphasized focus on three pillars: quality care, operational rigor, and financial discipline. 
- Robotics and ASC expansions highlight innovation, with robotic surgery caseloads growing significantly. 
- Transfer center operations provide insights for future capacity and service line investments. 

**【CFO Financial Commentary】**
- Adjusted EBITDA of $376 million (11.9% margin) reflects stable performance despite headwinds from payer downgrades. 
- Debt refinancing includes $700M senior notes at 10.75% and a $626M tender offer for 6.875% notes, reducing leverage to 7.1x. 
- Free cash flow improved to $120M Q1 vs. $96M prior year, driven by $80M tax refunds. 
- Medical specialist fees up 9% YoY (anesthesia dominant), with in-sourcing initiatives to mitigate costs. 
- 2025 guidance unchanged, excluding potential DPP approvals ($100-125M EBITDA boost). 

**【Q&A Key Themes】**
- **Payer Behavior & Costs**: Denials/downgrades stable but persistent; anesthesia fees up 9% YoY. 
- **Divestitures & Balance Sheet**: $1B+ proceeds used for debt reduction; Cedar Park sale expected Q2/Q3. 
- **Market Trends**: Strong EMS/trauma volumes; GI procedures soft due to deductible resets. 
- **Tariffs Impact**: <5% of supplies from China; GPO contracts protect against price volatility. 
- **DPP Programs**: Tennessee/New Mexico approvals pending; Indiana program in legislative process.

Community Health Systems (CYH)-24 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: Same-store admissions +2.7%, surgeries +14% on 47 ASCs/19 FSEDs
- **Profitability**: 6% EBITDA growth to $1.54B, 13.1% margin
- **Cost Control**: Labor savings 36%, supplies 60bps improvement
- **Strategic Sales**: >$1B asset sales to reduce 7.4x leverage
- **Risks**: Medical specialist fees +10.9%, DPP program approvals pending

**【CEO Summary Section】**
- **Record Volume Growth**: Full-year same-store adjusted admissions increased 2.7%, surgeries up 14%, driven by outpatient expansion (47 ASCs, 19 FSEDs) and strategic acquisitions (10 urgent care clinics, 2 FSEDs). 
- **Operational Efficiency**: Same-store net operating revenues +5.5%, adjusted EBITDA +6% (including $40M Medicaid DPP benefit). Labor/supplies as % of revenue improved 50bps.
- **Portfolio Optimization**: Completed $550M+ asset sales (Cleveland, TN; Lake Norman, NC), targeting >$1B proceeds in 2025. 
- **Clinical Excellence**: 90% reduction in serious safety events vs. 2013 baseline; RN retention best in 5 years.

**【CFO Financial Commentary】**
- **Q4 Results**: Adjusted EBITDA $428M (+11% YoY), margin 13.1%. Full-year EBITDA $1.54B (+6%).
- **Cost Management**: 
  - Labor: Hourly rates +4.7% (vs. +11% in 2023)
  - Supplies: 15.5% of revenue (-60bps YoY)
  - Contract labor down 36% YoY to $170M
- **Challenges**: Medical specialist fees +10.9% YoY ($640M total), partially offset by $40M DPP benefit.
- **Cash Flow**: 2024 cash from ops $480M vs. $210M prior year. 2025 guidance: $600-700M cash flow, $350-400M capex.
- **Leverage**: Net debt/EBITDA 7.4x (down from 7.9x YoY).

Actual											-1.59	0.85	0.18	0.96	0.36	0.23	0.69	1.15	0.14	-2.52	-0.52	1.5	-0.43	-0.22	-0.33	-0.41	-0.14	-0.17	-0.3	-0.42	-0.03	-0.05	1.27	-0.01
Forecast											-0.5842	-0.9494	-0.3684	-0.0376	-0.1619	-0.0032	0.1255	0.6111	0.0639	0.0455	-0.0194	0.3473	-0.1832	-0.2612	-0.1556	0.0522	-0.1618	-0.1357	-0.2117	0.0819	-0.079	-0.1046	-0.2475	-0.0507
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-172.17%	+189.53%	+148.86%	+2653.19%	+322.36%	+7287.50%	+449.80%	+88.19%	+119.09%	-5638.46%	-2580.41%	+331.90%	-134.72%	+15.77%	-112.08%	-885.44%	+13.47%	-25.28%	-41.71%	-612.82%	+62.03%	+52.20%	+613.13%	+80.28%

CYH

CYH fundamentals

CYH Q4 2025 Earnings

Earnings Call

You can ask Aime

CYH

CYH fundamentals

CYH Q4 2025 Earnings

Earnings Call

CYH Earnings Call Summary for Q4/202511:00 AM on Feb 19, 2026

CYH Earnings Call Summary for Q3/202511:00 AM on Oct 24, 2025

CYH Earnings Call Summary for Q2/202511:00 AM on Jul 24, 2025

CYH Earnings Call Summary for Q1/202511:00 AM on Apr 24, 2025

CYH Earnings Call Summary for Q4/202411:00 AM on Feb 19, 2025

You can ask Aime